Quick Answer
BioXcel Therapeutics, Inc. reported Total Revenue of $642.0 thousand for fiscal year 2025.
BioXcel Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $642.0K -71.7% |
$2.27M +64.2% |
$1.38M +268.0% |
$375.0K | — | — |
| Revenue (ASC 606) | $642.0K -71.7% |
$2.27M +64.2% |
$1.38M +268.0% |
$375.0K | — | — |
| Net Income | -$69.90M -17.3% |
-$59.60M +66.7% |
-$179.05M -8.0% |
-$165.76M -55.0% |
-$106.93M -30.1% |
-$82.17M -149.2% |
| Diluted EPS | -$5.73 +75.6% |
-$23.51 +76.1% |
-$98.33 -1561.0% |
-$5.92 -46.2% |
-$4.05 -6.9% |
-$3.79 |
| Total Assets | $44.92M +17.2% |
$38.34M -48.0% |
$73.70M -64.2% |
$205.85M -14.0% |
$239.44M +8.9% |
$219.94M +504.4% |
| Cash and Equivalents | $28.41M -4.8% |
$29.85M -54.2% |
$65.22M -66.3% |
$193.72M -16.8% |
$232.97M +9.3% |
$213.12M +557.2% |
| Long-Term Debt | $84.66M -17.4% |
$102.51M +1.9% |
$100.60M +8.1% |
$93.05M | — | — |
| Stockholders Equity | -$95.46M -2.5% |
-$93.10M -64.8% |
-$56.51M -173.6% |
$76.78M -65.4% |
$221.67M +7.2% |
$206.70M +668.5% |
| R&D Expense | $30.25M -0.6% |
$30.43M -63.9% |
$84.33M -7.6% |
$91.24M +73.1% |
$52.71M -9.1% |
$57.99M +124.8% |
| Operating Income | -$50.46M +25.0% |
-$67.25M +60.9% |
-$171.78M -7.6% |
-$159.65M -49.3% |
-$106.94M -29.9% |
-$82.30M -144.9% |
| Shares Outstanding | 22.33M +619.8% |
3.10M +65.8% |
1.87M -93.4% |
28.15M +0.6% |
27.98M +14.6% |
24.42M +35.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $98.0K | -54.2% | -18.3% |
| Revenue (ASC 606) | September 30, 2025 | $98.0K | -54.2% | -18.3% |
| Net Income | September 30, 2025 | -$30.91M | -126.5% | -61.1% |
| Diluted EPS | September 30, 2025 | -$2.18 | +57.7% | +11.0% |
| Total Assets | September 30, 2025 | $44.79M | -8.4% | +73.7% |
| Cash and Equivalents | September 30, 2025 | $36.18M | -10.4% | +107.5% |
| Long-Term Debt | September 30, 2025 | $92.30M | -11.6% | -5.3% |
| Stockholders Equity | September 30, 2025 | -$88.92M | -3.8% | +17.4% |
| R&D Expense | September 30, 2025 | $8.74M | +71.3% | -14.8% |
| Operating Income | September 30, 2025 | -$14.23M | +7.0% | +10.2% |
| Shares Outstanding | September 30, 2025 | 20.00M | -52.9% | +202.1% |
- BioXcel Therapeutics, Inc. reported Total Revenue of $642.0 thousand for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -71.7% in Total Revenue compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Revenue (ASC 606) of $642.0 thousand for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -71.7% in Revenue (ASC 606) compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Net Income of -$69.90 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -17.3% in Net Income compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Diluted EPS of $5.73 per share (loss) for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed an increase of +75.6% in Diluted EPS compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Total Assets of $44.92 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed an increase of +17.2% in Total Assets compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Cash and Equivalents of $28.41 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -4.8% in Cash and Equivalents compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Long-Term Debt of $84.66 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -17.4% in Long-Term Debt compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Stockholders Equity of -$95.46 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -2.5% in Stockholders Equity compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported R&D Expense of $30.25 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed a decrease of -0.6% in R&D Expense compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Operating Income of -$50.46 million for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed an increase of +25.0% in Operating Income compared to the prior fiscal year.
- BioXcel Therapeutics, Inc. reported Shares Outstanding of 22.33 million shares for fiscal year 2025.
- BioXcel Therapeutics, Inc. showed an increase of +619.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: